Acacia Pharma has a portfolio of approved and near-market products targeting large and growing markets with significant unmet medical needs.
Postoperative nausea & vomiting (PONV)
PONV is a common complication of surgery, occurring in approximately 30% of surgical patients and up to 80% of high-risk patients.
View PONV video
For use during invasive medical procedures, such as colonoscopy and bronchoscopy.
Chemotherapy induced nausea & vomiting (CINV)
CINV is one of the most common and feared side effects of cancer chemotherapy.
Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
View all news